Affiliation:
1. Hospital Sírio-Libanês, Brazil
2. Universidade de São Paulo, Brazil
3. Universidade de São Paulo, Brazil; Instituto do Câncer do Estado de São Paulo, Brazil
Abstract
AbstractLung cancer is the leading cause of cancer-related deaths worldwide. Promising new therapies have recently emerged from the development of molecular targeted drugs; particularly promising are those blocking the signal transduction machinery of cancer cells. One of the most widely studied cell signaling pathways is that of EGFR, which leads to uncontrolled cell proliferation, increased cell angiogenesis, and greater cell invasiveness. Activating mutations in the EGFR gene (deletions in exon 19 and mutation L858R in exon 21), first described in 2004, have been detected in approximately 10% of all non-squamous non-small cell lung cancer (NSCLC) patients in Western countries and are the most important predictors of a response to EGFR tyrosine-kinase inhibitors (EGFR-TKIs). Studies of the EGFR-TKIs gefitinib, erlotinib, and afatinib, in comparison with platinum-based regimens, as first-line treatments in chemotherapy-naïve patients have shown that the EGFR-TKIs produce gains in progression-free survival and overall response rates, although only in patients whose tumors harbor activating mutations in the EGFR gene. Clinical trials have also shown EGFR-TKIs to be effective as second- and third-line therapies in advanced NSCLC. Here, we review the main aspects of EGFR pathway activation in NSCLC, underscore the importance of correctly identifying activating mutations in the EGFR gene, and discuss the main outcomes of EGFR-TKI treatment in NSCLC.
Subject
Pulmonary and Respiratory Medicine
Reference75 articles.
1. Estimativa 2014 - Incidência de Câncer no Brasil 2014,2014
2. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11[monograph_on_the_internet];Ferlay J,2013
3. Mortality distribution due to tracheal, lung, and bronchial cancer by gender, Brazil, 1980-2010;Guimarães RM;J Bras Pneumol,2013
4. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller JH;N Engl J Med,2002
5. EGFR mutations in lung cancer correlation with clinical response to gefitinib therapy;Paez JG;Science,2004
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献